Sequencing-based measurable residual disease testing in acute myeloid leukemia

Next generation sequencing (NGS) methods have allowed for unprecedented genomic characterization of acute myeloid leukemia (AML) over the last several years. Further advances in NGS-based methods including error correction using unique molecular identifiers (UMIs) have more recently enabled the use of NGS-based measurable residual disease (MRD) detection. This review focuses on the use of NGS-based MRD detection in AML, including basic methodologies and clinical applications

Sex differences in animal models of decision making

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/137573/1/jnr23810.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/137573/2/jnr23810_am.pd

Case history of a politically charged issue - wild pigs in Tennessee, A

Moderator: Billy Higginbotham.Presented at the 8th international congress for wildlife and livelihoods on private and communal lands: livestock, tourism, and spirit, that was held on September 7-12, 2014 in Estes Park, Colorado.In 2010 the Tennessee Wildlife Resources Agency (TWRA) acknowledged the failure of harvest-based management to control wild hog (Sus scrofa) populations and the need to shift focus to a more aggressive statewide wild hog eradication program. Recognizing the problem was beyond the scope of the TWRA, organizations were invited to partner in the future of Tennessee's wild hog management. This nascent group focused on proven methods used in states with much smaller hog populations based on three tenets: 1) eliminating incentives to illegally transport and release wild hogs, 2) increasing opportunities for landowners to control wild hogs, 3) and outreach. Following these tenets, wild hog populations have been lowered and some disjunction pockets eliminated across the state. These accomplishments would not be possible by any entity (e.g., TWRA) acting alone. Success is due to the partnership known as the Wild Hog Eradication Action Team (WHEAT) which grew from four partners to a 24 member organization leading wild hog management in Tennessee. WHEAT brings great value to statewide implementation of the three tenets through development of hog management regulations, collaborative outreach, and lobbying. Program success is due to the diversity of partnerships and the ability to guide efforts, remove obstacles, and educate. Recent shifts in Tennessee’s wild hog management likely would have failed without the contributions of WHEAT. As a result, we recommend any agencies considering major shifts in wild hog management: 1) do not implement a harvest-based program; 2) adopt the three tenets; and 3) develop an overarching, guiding partnership

Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review

Jennifer M Yoest Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA Abstract: Identification and characterization of T-cell regulatory mechanisms, or checkpoints, have led to a wave of drug development aimed at inhibiting these targets to “remove the brakes” of the immune system. This class of anticancer therapeutics, termed immune checkpoint inhibitors (ICIs), has harnessed the potential of the body’s own immune system to recognize cancerous cells and selectively eliminate them, in some cases with alarming success. This new breakthrough, however, has not been without its drawbacks. Immune-related adverse events (irAEs) are adverse events encountered during treatment with ICIs that are thought to be mediated through the patient’s immune system which can manifest with a variety of symptoms which often resemble autoimmunity. These events range widely in presentation and severity and are reported frequently. Here, we will discuss a large selection of case reports in order to inform the clinician, laboratorian, and researcher of the scope of organ systems affected, the severity of the conditions being encountered, and the responses of these events to treatment, as well as explore the use of ICIs in the setting of preexisting autoimmunity. We will also consider the ability to detect autoantibodies before and during irAEs as well as the correlations that irAEs have with clinical outcomes. Finally, we will conclude by exploring the possibility that two distinct pathways may be contributing to the phenomenon of irAEs within this class of drugs, and the role that this might play in future research and clinical practice. Keywords: immune checkpoint inhibitors, immune-related adverse events, side effects, autoimmunity, etiology, prediction, cross-reactive, correlation with tumor respons